Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00629525 · ClinicalTrials.gov registry record · Phase 2
RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
A Phase 2 study of Hormone-refractory Prostate Cancer, sponsored by Daniel George, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00629525: Completed Phase 2 study of Hormone-refractory Prostate Cancer, sponsored by Daniel George, MD.
NCT00629525 is a Phase 2 study of Hormone-refractory Prostate Cancer that has completed, run by Daniel George, MD. The registered enrollment target is 35 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00629525, a Phase 2 study of Hormone-refractory Prostate Cancer, has completed, sponsored by Daniel George, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
Primary Outcome
Number of participants with 50% decline in serum PSA from baseline was pre-set as the primary measure of disease response.
Conditions Studied
Interventions
- DRUG RAD001
Study Locations (1)
North Carolina
- Duke University MEdical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-08 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00629525 record still lists
NCT00629525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Hormone-refractory Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which RAD001 is the first listed.
NCT00629525 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT00629525 about?
NCT00629525 is a clinical study titled "RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer". The purpose of this study is to determine the biochemical response rate (PSA) to single agent RAD001 in patients with metastatic hormone-refractory prostate cancer (HRPC).
What is the current status of trial NCT00629525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2005-08. Estimated completion is 2010-01.
What conditions does trial NCT00629525 study?
This clinical trial studies the following conditions: Hormone-refractory Prostate Cancer.
What interventions are being tested in trial NCT00629525?
The interventions under investigation include: RAD001 (DRUG).
Who is sponsoring clinical trial NCT00629525?
This trial is sponsored by Daniel George, MD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00629525 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hormone-refractory Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00629525's enrollment target sits among peer trials
35 1524th of 2000 higher than 462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia